1887

Abstract

Antiretroviral therapy (ART) can control human immunodeficiency virus-1 (HIV-1) replication in infected individuals. Unfortunately, patients remain persistently infected owing to the establishment of latent infection requiring that ART be maintained indefinitely. One strategy being pursued involves the development of latency-reversing agents (LRAs) to eliminate the latent arm of the infection. One class of molecules that has been tested for LRA activity is the epigenetic modulating compounds histone deacetylases inhibitors (HDACis). Previously, initial screening of these molecules typically commenced using established cell models of viral latency, and although certain drugs such as the HDACi suberoylanilide hydroxamic acid demonstrated strong activity in these models, it did not translate to comparable activity with patient samples. Here we developed a primary cell model of viral latency using primary resting CD4 T cells infected with Vpx-complemented HIV-1 and found that the activation profile using previously described LRAs mimicked that obtained with patient samples. This primary cell model was used to evaluate 94 epigenetic compounds. Not surprisingly, HDACis were found to be the strongest activators. However, within the HDACi class, the most active LRAs with the least pronounced toxicity contained a benzamide functional moiety with a pyridyl cap group, as exemplified by the HDACi chidamide. The results indicate that HDACis with a benzamide moiety and pyridyl cap group should be considered for further drug development in the pursuit of a successful viral clearance strategy.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000716
2017-04-27
2019-10-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/4/799.html?itemId=/content/journal/jgv/10.1099/jgv.0.000716&mimeType=html&fmt=ahah

References

  1. UNAIDS.. 2016; . Fact sheet – Latest statistics on the status of the AIDS epidemic.. www.unaids.org/en/resources/fact-sheet
  2. Durand CM, Blankson JN, Siliciano RF. Developing strategies for HIV-1 eradication. Trends Immunol 2012;33:554–562 [CrossRef][PubMed]
    [Google Scholar]
  3. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012;37:377–388 [CrossRef][PubMed]
    [Google Scholar]
  4. Lassen K, Han Y, Zhou Y, Siliciano J, Siliciano RF. The multifactorial nature of HIV-1 latency. Trends Mol Med 2004;10:525–531 [CrossRef][PubMed]
    [Google Scholar]
  5. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012;36:491–501 [CrossRef][PubMed]
    [Google Scholar]
  6. Mbonye U, Karn J. Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology 2014;454-455:328–339 [CrossRef][PubMed]
    [Google Scholar]
  7. Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ et al. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 2009;83:4749–4756 [CrossRef][PubMed]
    [Google Scholar]
  8. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y et al. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA 1997;94:2927–2932 [CrossRef][PubMed]
    [Google Scholar]
  9. Du Chéné I, Basyuk E, Lin YL, Triboulet R, Knezevich A et al. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J 2007;26:424–435 [CrossRef][PubMed]
    [Google Scholar]
  10. Imai K, Togami H, Okamoto T. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem 2010;285:16538–16545 [CrossRef][PubMed]
    [Google Scholar]
  11. Friedman J, Cho WK, Chu CK, Keedy KS, Archin NM et al. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol 2011;85:9078–9089 [CrossRef][PubMed]
    [Google Scholar]
  12. Blazkova J, Trejbalova K, Gondois-Rey F, Halfon P, Philibert P et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 2009;5:e1000554 [CrossRef][PubMed]
    [Google Scholar]
  13. Rafati H, Parra M, Hakre S, Moshkin Y, Verdin E et al. Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency. PLoS Biol 2011;9:e1001206 [CrossRef][PubMed]
    [Google Scholar]
  14. Coiras M, López-Huertas MR, Pérez-Olmeda M, Alcamí J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 2009;7:798–812 [CrossRef][PubMed]
    [Google Scholar]
  15. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487:482–485 [CrossRef][PubMed]
    [Google Scholar]
  16. Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med 2012;13:291–296 [CrossRef][PubMed]
    [Google Scholar]
  17. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 2014;1:e13e21 [CrossRef][PubMed]
    [Google Scholar]
  18. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011;474:658–661 [CrossRef][PubMed]
    [Google Scholar]
  19. Sunseri N, O'Brien M, Bhardwaj N, Landau NR. Human immunodeficiency virus type 1 modified to package Simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells. J Virol 2011;85:6263–6274 [CrossRef][PubMed]
    [Google Scholar]
  20. Miller LK, Kobayashi Y, Chen CC, Russnak TA, Ron Y et al. Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication. Retrovirology 2013;10:120 [CrossRef][PubMed]
    [Google Scholar]
  21. Pertel T, Reinhard C, Luban J. Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon. Retrovirology 2011;8:49 [CrossRef][PubMed]
    [Google Scholar]
  22. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W et al. SAMHD1 restricts HIV-1 infection in resting CD4+ T cells. Nat Med 2012;18:1682–1687 [CrossRef][PubMed]
    [Google Scholar]
  23. Sahu GK, Lee K, Ji J, Braciale V, Baron S et al. A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes. Virology 2006;355:127–137 [CrossRef][PubMed]
    [Google Scholar]
  24. Tyagi M, Pearson RJ, Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 2010;84:6425–6437 [CrossRef][PubMed]
    [Google Scholar]
  25. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067–1073 [CrossRef][PubMed]
    [Google Scholar]
  26. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996;93:5705–5708 [CrossRef][PubMed]
    [Google Scholar]
  27. Pettit GR, Herald CL, Doubek DL, Herald DL, Arnold E et al. Isolation and structure of bryostatin 1. J Am Chem Soc 1982;104:6846–6848 [CrossRef]
    [Google Scholar]
  28. Gustafson KR, Cardellina JH 2nd, Mcmahon JB, Gulakowski RJ, Ishitoya J et al. A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem 1992;35:1978–1986 [CrossRef][PubMed]
    [Google Scholar]
  29. Hecker E. Phorbol esters from croton oil chemical nature and biological activities. Naturwissenschaften 1967;54:282–284 [CrossRef][PubMed]
    [Google Scholar]
  30. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 2015;125:1901–1912 [CrossRef][PubMed]
    [Google Scholar]
  31. Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M Jr et al. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2014;111:7078–7083 [CrossRef][PubMed]
    [Google Scholar]
  32. Amarnath S, Dong L, Li J, Wu Y, Chen W. Endogenous TGF-β activation by reactive oxygen species is key to Foxp3 induction in TCR-stimulated and HIV-1-infected human CD4+ CD25-T cells. Retrovirology 2007;4:57 [CrossRef][PubMed]
    [Google Scholar]
  33. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 2014;10:e1004071 [CrossRef][PubMed]
    [Google Scholar]
  34. Wightman F, Lu HK, Solomon AE, Saleh S, Harman AN et al. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS 2013;27:2853–2862 [CrossRef][PubMed]
    [Google Scholar]
  35. Micheva-Viteva S, Pacchia AL, Ron Y, Peltz SW, Dougherty JP. Human immunodeficiency virus type 1 latency model for high-throughput screening. Antimicrob Agents Chemother 2005;49:5185–5188 [CrossRef][PubMed]
    [Google Scholar]
  36. Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 2015;20:3898–3941 [CrossRef][PubMed]
    [Google Scholar]
  37. Chou CJ, Herman D, Gottesfeld JM. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem 2008;283:35402–35409 [CrossRef][PubMed]
    [Google Scholar]
  38. Shirakawa K, Chavez L, Hakre S, Calvanese V, Verdin E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 2013;21:277–285 [CrossRef][PubMed]
    [Google Scholar]
  39. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84–90 [CrossRef][PubMed]
    [Google Scholar]
  40. Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 2003;9:5749–5755[PubMed]
    [Google Scholar]
  41. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010;6:238–243 [CrossRef][PubMed]
    [Google Scholar]
  42. Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol 2013;8:1324–1334 [CrossRef][PubMed]
    [Google Scholar]
  43. Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L et al. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients. AIDS 2012;26:1473–1482 [CrossRef][PubMed]
    [Google Scholar]
  44. Donnelly ML, Luke G, Mehrotra A, Li X, Hughes LE et al. Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol 2001;82:1013–1025 [CrossRef][PubMed]
    [Google Scholar]
  45. Swiggard WJ, Baytop C, Yu JJ, Dai J, Li C et al. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol 2005;79:14179–14188 [CrossRef][PubMed]
    [Google Scholar]
  46. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 2014;20:425–429 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000716
Loading
/content/journal/jgv/10.1099/jgv.0.000716
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error